GHRP-1 vs PEG-MGF.

GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.

PEG-MGF is a PEGylated synthetic peptide based on the unique C-terminal E-domain of mechano growth factor (MGF), an alternatively spliced isoform of insulin-like growth factor-1 known as IGF-1Ec (the rodent equivalent is IGF-1Eb). MGF is produced locally by skeletal muscle in response to mechanical loading or damage; the research peptide reproduces its distinctive 24-amino-acid E-peptide rather than the full IGF-1 molecule. The polyethylene glycol (PEG) moiety is a chemical modification intended to slow degradation of the otherwise very short-lived native peptide. It is a research-use-only chemical, not an approved drug.

GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.

Native MGF arises when the IGF-1 gene is alternatively spliced after mechanical stress, producing a transcript whose distinct C-terminal "E-domain" differs from the IGF-1Ea isoform. The Goldspink group's central proposal, supported by cell-culture work, is that the MGF E-peptide acts to expand the pool of muscle satellite (stem) cells by promoting myoblast proliferation while delaying their differentiation, whereas mature IGF-1 drives differentiation and protein synthesis through the IGF-1 receptor (Yang & Goldspink, FEBS Lett 2002). Notably, several studies report that the isolated E-domain peptide exerts effects that do not appear to require classical IGF-1 receptor binding, implying a separate, still incompletely defined receptor/signaling pathway. PEGylation is intended only to lengthen circulating half-life and does not change this proposed biology.

The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.

The human evidence base for PEG-MGF specifically is essentially absent: no completed human clinical trials evaluating the PEGylated peptide for any indication could be identified. The underlying MGF biology rests on preclinical and ex vivo work, much of it from Geoffrey Goldspink's UCL group: mechanical stretch and stimulation induce an IGF-1 splice variant in rabbit and rodent muscle (Yang et al., J Physiol 1999; Hill & Goldspink, J Physiol 2003), the MGF E-peptide and mature IGF-1 play distinct proliferation-vs-differentiation roles in cultured myoblasts (Yang & Goldspink, FEBS Lett 2002), and a synthetic MGF E-peptide can act through a mechanism distinct from the IGF-1 receptor (Mills et al., 2007) and improve myogenic precursor cell transplantation in animals (Am J Transplant 2007). Animal studies have also explored MGF in acute myocardial infarction (Carpenter et al., Heart Lung Circ 2008) and neuronal injury models. These data establish biological plausibility for muscle repair signaling but do not demonstrate safety or efficacy of PEG-MGF in humans, and findings in cell/animal systems frequently fail to translate.

Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.

There is no human safety data for PEG-MGF; it has not undergone formal toxicology or clinical evaluation, so its adverse-effect profile, immunogenicity, and long-term risks in people are unknown. As a peptide in the IGF-1 family that promotes cell proliferation, a theoretical concern is unwanted stimulation of growth in non-target or abnormal tissues, though this has not been characterized for this molecule. PEGylated therapeutics as a class can elicit anti-PEG antibodies and, rarely, injection-site or hypersensitivity reactions, but whether this applies to PEG-MGF is unstudied. Research-grade material also carries quality, purity, and contamination uncertainties because it is not manufactured to pharmaceutical standards.

GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.

PEG-MGF is not approved by the FDA or any major regulatory agency for any use and is sold only as a research-use-only chemical, not for human consumption. The mechano growth factor E-domain peptide is prohibited in sport: WADA lists growth factors affecting muscle, including MGF, under category S2 (peptide hormones, growth factors, related substances).